Application
Research CategoryApoptosis & Cancer
Research Sub CategoryApoptosis - Additional
Anti-Nop30 Antibody is a highly specific rabbit polyclonal antibody, that targets Nucleolar protein 3 & has been tested in western blotting.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
Apoptosis, also known as programmed cell death, plays major roles in development and normal tissue turnover in addition to tumor formation. Nop30 (also known as Nucleolar protein 3, Apoptosis repressor with CARD, Muscle-enriched cytoplasmic protein, Myp, Nucleolar protein of 30 kDa, and Nop30) is an alternate splicing isoform of ARC. While ARC interacts with caspase-2 and –8 and suppresses apoptosis induced by cell death adapters FADD and TRADD and by cell death receptors Fas, TNFR-1 and DR3, Nop30 multimerizes and binds to the splicing factor SRp30c and may act to influence alternative splice site selection in vivo.
Immunogen
KLH-conjugated linear peptide corresponding to a 14 amino acid peptide near the C-terminus of human Nop30.
Epitope: C-terminus
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Physical form
Antigen Affinity Purified
Purified rabbit polyclonal in buffer containing PBS with up to 0.1% sodium azide.
Quality
Evaluated by Western Blotting in mouse muscle tissue lysate.
Western Blotting Analysis: 2 µg/mL of this antibody detected Nop30 in mouse muscle tissue lysate.
Specificity
This Nop30 antibody will not detect ARC protein.
Storage and Stability
Stable for 1 year at 2-8°C from date of receipt.
Target description
~24 kDa observed. Uncharacterized bands may be observed in some lysate(s).
This product has met the following criteria to qualify for the following awards: